Methods of overcoming treatment resistance in colorectal cancer

Sally Temraz; Deborah Mukherji; Raafat Alameddine; Ali Shamseddine

doi:10.1016/j.critrevonc.2013.08.015

Methods of overcoming treatment resistance in colorectal cancer

Crit Rev Oncol Hematol. 2014 Feb;89(2):217-30. doi: 10.1016/j.critrevonc.2013.08.015. Epub 2013 Sep 8.

Authors

Sally Temraz¹, Deborah Mukherji², Raafat Alameddine², Ali Shamseddine²

Affiliations

¹ American University of Beirut Medical Center (AUBMC), Lebanon. Electronic address: St29@aub.edu.lb.
² American University of Beirut Medical Center (AUBMC), Lebanon.

PMID: 24075059
DOI: 10.1016/j.critrevonc.2013.08.015

Abstract

Metastatic colorectal cancer remains a lethal disease with a poor prognosis in the majority of patients. Multiple drug combinations have been developed in recent years that have significantly improved response rates and overall survival however resistance to these drugs is inevitable. Novel agents are currently being developed and participation in clinical trials should be encouraged. In the absence of other treatment options in a patient with good performance status, there is compelling evidence for re-challenging with previously administered agents in different combinations. The aim of this review is to discuss mechanisms of resistance and methods to overcome treatment resistance in patients with metastatic colorectal cancer who are refractory to 5-FU, irinotecan, oxaliplatin, cetuximab and bevacizumab therapy.

Keywords: 5-Fluorouracil; Bevacizumab; Cetuximab; Drug resistance; Irinotecan; Overcome resistance; Oxaliplatin; Re-challenge.

Publication types

Review

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / pharmacology
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bevacizumab
Camptothecin / administration & dosage
Camptothecin / analogs & derivatives
Camptothecin / pharmacology
Camptothecin / therapeutic use
Cetuximab
Colon / drug effects
Colon / pathology
Colorectal Neoplasms / drug therapy*
Drug Resistance, Neoplasm*
Fluorouracil / administration & dosage
Fluorouracil / pharmacology
Fluorouracil / therapeutic use
Humans
Irinotecan
Organoplatinum Compounds / administration & dosage
Organoplatinum Compounds / pharmacology
Organoplatinum Compounds / therapeutic use
Oxaliplatin
Rectum / drug effects
Rectum / pathology

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Organoplatinum Compounds
Oxaliplatin
Bevacizumab
Irinotecan
Cetuximab
Fluorouracil
Camptothecin